Haloperidol
Haldol, Haloperidol (haloperidol) is a small molecule pharmaceutical. Haloperidol was first approved as Haldol on 1982-01-01. It is used to treat child behavior disorders, psychotic disorders, schizophrenia, schizophrenia spectrum and other psychotic disorders, and substance withdrawal syndrome amongst others in the USA. The pharmaceutical is active against D(3) dopamine receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 2A, and D(2) dopamine receptor. In addition, it is known to target D(1A) dopamine receptor, G protein-activated inward rectifier potassium channel 2, D(1B) dopamine receptor, 5-hydroxytryptamine receptor 7, voltage-gated delayed rectifier potassium channel KCNH1; potassium voltage-gated channel subfamily H member 1, 5-hydroxytryptamine receptor 1D, 5-hydroxytryptamine receptor 2B, histamine H1 receptor, and 5-hydroxytryptamine receptor 1A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Haloperidol (discontinued: Haldol, Haloperidol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Haloperidol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HALDOL | Johnson & Johnson | N-015921 DISCN | 1982-01-01 | 6 products, RLD |
| HALDOL SOLUTAB | Johnson & Johnson | N-017079 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Haloperidol lactate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HALDOL | Johnson & Johnson | N-015923 DISCN | 1982-01-01 | 1 products, RLD |
| HALDOL | Johnson & Johnson | N-015922 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| haldol decanoate | New Drug Application | 2025-01-30 |
| haloperidol | ANDA | 2025-03-26 |
| haloperidol decanoate | ANDA | 2025-02-28 |
| haloperidol lactate | ANDA | 2024-12-30 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
192 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 5 | 12 | 25 | 18 | 59 |
| Delirium | D003693 | — | R41.0 | — | 9 | 17 | 11 | 7 | 40 |
| Psychotic disorders | D011618 | — | F20.81 | 1 | 2 | 11 | 11 | 4 | 28 |
| Psychomotor agitation | D011595 | — | — | — | 3 | 8 | 10 | 6 | 26 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | 2 | 9 | 4 | 1 | 15 |
| Vomiting | D014839 | — | R11.1 | 1 | 1 | 2 | 5 | 3 | 12 |
| Nausea | D009325 | — | R11.0 | 1 | — | 2 | 5 | 3 | 11 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 1 | 4 | 1 | 3 | 9 |
| Emergencies | D004630 | — | — | — | 1 | 1 | 5 | 1 | 8 |
| Neoplasms | D009369 | — | C80 | — | 3 | 4 | 1 | 1 | 7 |
Show 34 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | — | 3 | 2 | — | 1 | 4 |
| Critical illness | D016638 | — | — | — | 1 | 1 | — | 2 | 4 |
| Anesthesia | D000758 | — | — | — | — | 1 | — | 1 | 2 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 2 | — | — | 2 |
| Medication adherence | D055118 | EFO_0006344 | — | — | — | 1 | — | 1 | 2 |
| Hypokinesia | D018476 | — | — | — | — | 2 | — | — | 2 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | 1 | — | 1 | 2 |
| Heart arrest | D006323 | EFO_0009492 | I46 | — | — | 1 | — | 1 | 2 |
| Intellectual disability | D008607 | EFO_0003847 | F73 | — | 1 | 1 | — | — | 2 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | 1 | 2 | — | — | 2 |
Show 21 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Movement disorders | D009069 | EFO_0004280 | G25 | — | 1 | — | — | 2 | 3 |
| Artificial respiration | D012121 | — | — | — | 1 | — | — | 1 | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 1 | — | — | — | 1 |
| Fallopian tube neoplasms | D005185 | — | — | 1 | 1 | — | — | — | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 1 | 1 | — | — | — | 1 |
| Peritoneal neoplasms | D010534 | — | — | 1 | 1 | — | — | — | 1 |
| Intestinal obstruction | D007415 | — | K56.60 | 1 | 1 | — | — | — | 1 |
| Critical care | D003422 | — | — | — | 1 | — | — | — | 1 |
| Ventilator weaning | D015300 | — | — | — | 1 | — | — | — | 1 |
| Gambling | D005715 | EFO_1001926 | F63.0 | — | 1 | — | — | — | 1 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | 1 | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | 1 | 2 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Placebos | D010919 | — | — | 1 | — | — | — | — | 1 |
| Body weight | D001835 | EFO_0004338 | — | 1 | — | — | — | — | 1 |
| Weight gain | D015430 | — | — | 1 | — | — | — | — | 1 |
| Pharmacogenomic testing | D000071185 | — | — | 1 | — | — | — | — | 1 |
| Huntington disease | D006816 | Orphanet_399 | G10 | 1 | — | — | — | — | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
| Tobacco use disorder | D014029 | — | F17 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Long qt syndrome | D008133 | HP_0001657 | I45.81 | — | — | — | — | 2 | 2 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 2 | 2 |
| Dyslipidemias | D050171 | — | — | — | — | — | — | 2 | 2 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | — | 2 | 2 |
| Torsades de pointes | D016171 | EFO_0005307 | I47.21 | — | — | — | — | 1 | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
| Female genital diseases | D005831 | EFO_0009549 | N85 | — | — | — | — | 1 | 1 |
| Sleep deprivation | D012892 | — | F51.12 | — | — | — | — | 1 | 1 |
Show 61 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Haloperidol |
| INN | haloperidol |
| Description | Haloperidol is a compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. It has a role as a serotonergic antagonist, a first generation antipsychotic, a dopaminergic antagonist, an antidyskinesia agent and an antiemetic. It is a hydroxypiperidine, an organofluorine compound, an aromatic ketone, a tertiary alcohol and a member of monochlorobenzenes. |
| Classification | Small molecule |
| Drug class | antipsychotics (haloperidol type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 52-86-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL54 |
| ChEBI ID | 5613 |
| PubChem CID | 3559 |
| DrugBank | DB00502 |
| UNII ID | J6292F8L3D (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KCNH1
KCNH1
Organism
Homo sapiens
Gene name
KCNH1
Gene synonyms
EAG, EAG1
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily H member 1
Protein synonyms
EAG channel 1, ether-a-go-go 1, Ether-a-go-go potassium channel 1, ether-a-go-go, Drosophila, homolog of, h-eag, hEAG1, potassium channel, voltage gated eag related subfamily H, member 1, potassium voltage-gated channel, subfamily H (eag-related), member 1, Voltage-gated potassium channel subunit Kv10.1
Uniprot ID
Mouse ortholog
Kcnh1 (16510)
potassium voltage-gated channel subfamily H member 1 (Q60603)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Haloperidol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 32,969 documents
View more details
Safety
Black-box Warning
Black-box warning for: Haldol decanoate, Haloperidol, Haloperidol decanoate, Haloperidol lactate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
27,002 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use